ArticlemAbs2015
Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
Article in mAbs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Review
- Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation.Cell reports. Medicine · 2025Review
- Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent.Annals of nuclear medicine · 2025Article
- Antigen targeting and anti-tumor activity of a novel anti-CD146Scientific reports · 2024Article
- Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers.European journal of nuclear medicine and molecular imaging · 2024Article
- Review
- Targeted alpha therapy with theFrontiers in medicine · 2022Article
- A Novel Single-Step-LabeledMaterials (Basel, Switzerland) · 2021Article
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.Cancer biotherapy & radiopharmaceuticals · 2020Article
- Versatile Bispidine-Based Bifunctional Chelators forChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Article
- Development of Targeted Alpha Particle Therapy for Solid Tumors.Molecules (Basel, Switzerland) · 2019Review
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Exploration of a F(ab')Cancer biotherapy & radiopharmaceuticals · 2018Article
- Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.Translational oncology · 2017Article
- B7-H3-targetedNuclear medicine and biology · 2017Article
- Targeting metastasis.Nature reviews. Cancer · 2016Review
- Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.Pharmaceuticals (Basel, Switzerland) · 2015Article
Corrections and comments
- Erratum issuedErratum.2016
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Although the epidermal growth factor receptor (EGFR), also known as HER1, has been studied for over a decade, it continues to be a molecule of great interest and focus of investigators for development of targeted therapies. The marketed monoclonal antibody cetuximab binds to HER1, and thus might serve as the basis for creation of imaging or therapies that target this receptor. The potential of cetuximab as a vehicle for the delivery of α-particle radiation was investigated in an intraperitoneal tumor mouse model. The effective working dose of 10 μCi of (212)Pb-cetuximab was determined from a dose (10-50 μCi) escalation study. Toxicity, as indicated by the lack of animal weight loss, was not evident at the 10 μCi dose of (212)Pb-cetuximab. A subsequent study demonstrated (212)Pb-cetuximab had a therapeutic efficacy similar to that of (212)Pb-trastuzumab (p = 0.588). Gemcitabine given 24 h prior to (212)Pb-cetuximab increased the median survival from 174 d to 283 d, but carboplatin suppressed the effectiveness of (212)Pb-cetuximab. Notably, concurrent treatment of tumor-bearing mice with (212)Pb-labeled cetuximab and trastuzumab provided therapeutic benefit that was greater than either antibody alone. In conclusion, cetuximab proved to be an effective vehicle for targeting HER1-expressing tumors with α-radiation for the treatment of disseminated intraperitoneal disease. These studies provide further evidence that the multimodality therapy regimens may have greater efficacy and benefit in the treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.